期刊
JOURNAL OF CYSTIC FIBROSIS
卷 21, 期 5, 页码 856-860出版社
ELSEVIER
DOI: 10.1016/j.jcf.2022.04.019
关键词
CFTR modulator; CFTR variant; Variant interpretation; Non CF-causing variant; Clinical outcomes
资金
- U.S. C.F. Foundation [CUTTIN13A1]
In December 2020, the FDA expanded the list of CFTR variants approved for treatment from 39 to 183. However, clinicians should be aware that individuals with certain variants may not respond to or benefit from this therapy. Four categories of variants were identified as potentially not resulting in a clinical response to modulator treatment.
In December 2020, the U.S. Food and Drug Administration (FDA) expanded the list of CFTR variants ap-proved for treatment with CFTR modulators drugs from 39 to 183. Clinicians should be aware that indi-viduals harboring certain variants approved for treatment may not respond to or benefit from this ther-apy. After review, the expert panel leading the CFTR2 project identified four categories of variants that may not result in a clinical response to modulator treatment: 15 variants assigned as non CF-causing; 45 variants of unknown significance; six variants known or suspected to cause mis-splicing as their primary defect rather than an amino acid substitution; and eight variants known to occur together in cis with another deleterious variant not expected to lead to CFTR protein (nonsense or frameshift). The potential risks and benefits of CFTR modulator therapy should be considered carefully for individuals harboring these variants.(c) 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据